| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
|
Still deciding? Get samples of US$ 10/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Tofacitinib citrate |
| CAS | 540737-29-9 |
| MF | C16H20N6O.C6H8O7 |
| MW | 504.497 |
| Appearance | White Powder |
| Assay | 99%min |
| Single impurity | ≤0.1% |
| Usage | Treat rheumatoid arthritis |
| Dosage | 30 nM; intraperitoneal injectio |
(1).Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company for treating rheumatoid arthritis, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
(2). It can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine) . Tofacitinib citrate is approved by the daily dose of 2 times, each time 5mg. Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Tofacitinib citrate treatment showed significant improvement in clinical response and physical function.abbreviated as NAD+ and NADH respectively.
(1).Tofacitinib citrate is an oral, small molecule drug used to treat adults with moderate-to-severe, active rheumatoid arthritis who have not responded well to being treated with methotrexate. Methotrexate is a disease-modifying antirheumatic drug (DMARD) used to treat rheumatoid arthritis (RA).
(2).Tofacitinib acts to block the body's production of enzymes called Janus kinases (JAKs). JAKs play a role in joint inflammation in RA, which can cause pain, swelling and stiffness. If left untreated, RA inflammation could lead to joint erosions, and organ and tissue damage. It may be used alone or in combination with methotrexate or other DMARDs.
){kind=link}